Framework agreement for vutrisiran 25 mg

Summary

Amgros I/S is procuring the medicinal product vutrisiran, 25 mg injectable solution in a syringe, under a framework agreement for supply to Danish hospital pharmacies and hospitals, with possible resale to the Faroe Islands and Greenland. The procurement consists of one lot, with an estimated quantity of 99,999 units. The ordinary purchasing period is 1 May 2027 to 30 April 2028, with options for up to two extensions of up to six months each.